Fushtey I.M., MD, professor, O.A .Savchenko, Ph.D., Department of Therapy, Clinical Pharmacology and Endocrinology
Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine
Conclusions.
1. Addition of PulmoBREATHE® combined medicine of MoviHealth Company, Switzerland into the treatment scheme of patients with infectious acute bronchitis, leads to a significant normalization (P<0.05) of basic clinical manifestations of the disease: cough, shortness of breath, sputum and wheezing fade, intoxication, ventilation syndrome and normalization of the blood picture in comparison of control groups.
2. Addition of PulmoBREATHE® complex product of MoviHealth Company, Switzerland, into the scheme of treatment of patients with acute bronchitis with ventilation disfunction leads to significantly more earlier (P<0.05) and expressed recovery of the ventilation function of the bronchi.
3. It is observed high safety profile and good tolerability of the PulmoBREATHE® product MoviHealth, Switzerland.